445 related articles for article (PubMed ID: 22510516)
1. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.
Cheng Q; Chang JT; Geradts J; Neckers LM; Haystead T; Spector NL; Lyerly HK
Breast Cancer Res; 2012 Apr; 14(2):R62. PubMed ID: 22510516
[TBL] [Abstract][Full Text] [Related]
2. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of HSF1 in estrogen receptor positive breast cancer.
Gökmen-Polar Y; Badve S
Oncotarget; 2016 Dec; 7(51):84239-84245. PubMed ID: 27713164
[TBL] [Abstract][Full Text] [Related]
4. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
[TBL] [Abstract][Full Text] [Related]
5. Heat shock proteins create a signature to predict the clinical outcome in breast cancer.
Klimczak M; Biecek P; Zylicz A; Zylicz M
Sci Rep; 2019 May; 9(1):7507. PubMed ID: 31101846
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
7.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
8. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
[TBL] [Abstract][Full Text] [Related]
9. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
[TBL] [Abstract][Full Text] [Related]
10. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
Lamy PJ; Fina F; Bascoul-Mollevi C; Laberenne AC; Martin PM; Ouafik L; Jacot W
Breast Cancer Res; 2011 Feb; 13(1):R15. PubMed ID: 21288332
[TBL] [Abstract][Full Text] [Related]
11. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic analysis reveals that heat shock protein 90α is a potential diagnostic and prognostic biomarker for cancer.
Chen W; Li G; Peng J; Dai W; Su Q; He Y
Eur J Cancer Prev; 2020 Jul; 29(4):357-364. PubMed ID: 31567483
[TBL] [Abstract][Full Text] [Related]
13. Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells.
Giordano C; Vizza D; Panza S; Barone I; Bonofiglio D; Lanzino M; Sisci D; De Amicis F; Fuqua SA; Catalano S; Andò S
Mol Oncol; 2013 Jun; 7(3):379-91. PubMed ID: 23228483
[TBL] [Abstract][Full Text] [Related]
14. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
15. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
16. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome.
Umemura S; Shirane M; Takekoshi S; Kusakabe T; Itoh J; Egashira N; Tokuda Y; Mori K; Osamura YR
Br J Cancer; 2009 Mar; 100(5):764-71. PubMed ID: 19259095
[TBL] [Abstract][Full Text] [Related]
18. Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
Berezowska S; Novotny A; Bauer K; Feuchtinger A; Slotta-Huspenina J; Becker K; Langer R; Walch A
PLoS One; 2013; 8(7):e69098. PubMed ID: 23874879
[TBL] [Abstract][Full Text] [Related]
19. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Vallon-Christersson J; Grabau D; Arason A; Gunnarsson H; Agnarsson BA; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R25. PubMed ID: 20459607
[TBL] [Abstract][Full Text] [Related]
20. Expression of the Brn-3b transcription factor correlates with expression of HSP-27 in breast cancer biopsies and is required for maximal activation of the HSP-27 promoter.
Lee SA; Ndisang D; Patel C; Dennis JH; Faulkes DJ; D'Arrigo C; Samady L; Farooqui-Kabir S; Heads RJ; Latchman DS; Budhram-Mahadeo VS
Cancer Res; 2005 Apr; 65(8):3072-80. PubMed ID: 15833836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]